Biotechnology
Compare Stocks
5 / 10Stock Comparison
FTRE vs PRA vs IQV vs HCI vs CRL
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Property & Casualty
Medical - Diagnostics & Research
Insurance - Property & Casualty
Medical - Diagnostics & Research
FTRE vs PRA vs IQV vs HCI vs CRL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Insurance - Property & Casualty | Medical - Diagnostics & Research | Insurance - Property & Casualty | Medical - Diagnostics & Research |
| Market Cap | $1.47B | $1.27B | $30.32B | $1.99B | $8.98B |
| Revenue (TTM) | $2.71B | $1.08B | $16.63B | $927M | $4.03B |
| Net Income (TTM) | $-447M | $65M | $1.39B | $314M | $-185M |
| Gross Margin | 12.1% | 25.5% | 26.1% | 66.5% | 24.9% |
| Operating Margin | -1.1% | 8.4% | 13.9% | 47.9% | 11.8% |
| Forward P/E | 23.0x | 21.8x | 14.1x | 9.2x | 16.4x |
| Total Debt | $68M | $435M | $16.17B | $68M | $3.07B |
| Cash & Equiv. | $175M | $36M | $1.98B | $1.21B | $214M |
FTRE vs PRA vs IQV vs HCI vs CRL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 23 | May 26 | Return |
|---|---|---|---|
| Fortrea Holdings In… (FTRE) | 100 | 45.8 | -54.2% |
| ProAssurance Corpor… (PRA) | 100 | 163.1 | +63.1% |
| IQVIA Holdings Inc. (IQV) | 100 | 79.5 | -20.5% |
| HCI Group, Inc. (HCI) | 100 | 247.4 | +147.4% |
| Charles River Labor… (CRL) | 100 | 86.5 | -13.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FTRE vs PRA vs IQV vs HCI vs CRL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FTRE is the #2 pick in this set and the best alternative if momentum is your priority.
- +176.6% vs HCI's +2.4%
PRA ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 0.05, Low D/E 32.2%, current ratio 1.33x
- Beta 0.05, current ratio 1.33x
- Beta 0.05 vs FTRE's 2.35
IQV is the clearest fit if your priority is income & stability.
- Dividend streak 2 yrs, beta 1.33
HCI carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 20.2%, EPS growth 179.8%, 3Y rev CAGR 22.3%
- 436.8% 10Y total return vs IQV's 166.5%
- PEG 0.19 vs IQV's 0.35
- 20.2% revenue growth vs PRA's -2.7%
Among these 5 stocks, CRL doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.2% revenue growth vs PRA's -2.7% | |
| Value | Lower P/E (9.2x vs 16.4x) | |
| Quality / Margins | 33.9% margin vs FTRE's -16.5% | |
| Stability / Safety | Beta 0.05 vs FTRE's 2.35 | |
| Dividends | 1.0% yield; 2-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +176.6% vs HCI's +2.4% | |
| Efficiency (ROA) | 13.2% ROA vs FTRE's -16.3%, ROIC 6.8% vs -1.6% |
FTRE vs PRA vs IQV vs HCI vs CRL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FTRE vs PRA vs IQV vs HCI vs CRL — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCI leads in 4 of 6 categories
PRA leads 1 • FTRE leads 0 • IQV leads 0 • CRL leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HCI leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV is the larger business by revenue, generating $16.6B annually — 17.9x HCI's $927M. HCI is the more profitable business, keeping 33.9% of every revenue dollar as net income compared to FTRE's -16.5%. On growth, HCI holds the edge at +11.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.7B | $1.1B | $16.6B | $927M | $4.0B |
| EBITDAEarnings before interest/tax | $48M | $101M | $3.5B | $454M | $757M |
| Net IncomeAfter-tax profit | -$447M | $65M | $1.4B | $314M | -$185M |
| Free Cash FlowCash after capex | $215M | -$17M | $2.7B | $431M | $391M |
| Gross MarginGross profit ÷ Revenue | +12.1% | +25.5% | +26.1% | +66.5% | +24.9% |
| Operating MarginEBIT ÷ Revenue | -1.1% | +8.4% | +13.9% | +47.9% | +11.8% |
| Net MarginNet income ÷ Revenue | -16.5% | +6.0% | +8.3% | +33.9% | -4.6% |
| FCF MarginFCF ÷ Revenue | +8.0% | -1.6% | +16.1% | +46.4% | +9.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.3% | -2.0% | +8.4% | +11.9% | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +95.9% | +2.5% | +15.0% | +23.4% | -160.0% |
Valuation Metrics
HCI leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 6.1x trailing earnings, HCI trades at a 75% valuation discount to PRA's 24.9x P/E. Adjusting for growth (PEG ratio), HCI offers better value at 0.13x vs IQV's 0.56x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.5B | $1.3B | $30.3B | $2.0B | $9.0B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $1.7B | $44.5B | $844M | $11.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | 24.86x | 22.79x | 6.15x | -62.52x |
| Forward P/EPrice ÷ next-FY EPS est. | 23.00x | 21.76x | 14.06x | 9.19x | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.56x | 0.13x | — |
| EV / EBITDAEnterprise value multiple | 28.82x | 19.46x | 12.97x | 1.92x | 12.98x |
| Price / SalesMarket cap ÷ Revenue | 0.54x | 1.16x | 1.86x | 2.20x | 2.24x |
| Price / BookPrice ÷ Book value/share | 2.52x | 0.94x | 4.67x | 1.77x | 2.81x |
| Price / FCFMarket cap ÷ FCF | 16.68x | — | 14.78x | 4.47x | 17.31x |
Profitability & Efficiency
HCI leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
HCI delivers a 32.0% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-79 for FTRE. HCI carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), HCI scores 8/9 vs PRA's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -79.1% | +5.0% | +22.1% | +32.0% | -5.7% |
| ROA (TTM)Return on assets | -16.3% | +1.2% | +4.7% | +13.2% | -2.5% |
| ROICReturn on invested capital | -1.6% | +3.2% | +8.7% | +6.8% | +6.3% |
| ROCEReturn on capital employed | -1.4% | +4.0% | +11.0% | +40.6% | +8.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 | 4 | 8 | 4 |
| Debt / EquityFinancial leverage | 0.12x | 0.32x | 2.44x | 0.06x | 0.95x |
| Net DebtTotal debt minus cash | -$107M | $399M | $14.2B | -$1.1B | $2.9B |
| Cash & Equiv.Liquid assets | $175M | $36M | $2.0B | $1.2B | $214M |
| Total DebtShort + long-term debt | $68M | $435M | $16.2B | $68M | $3.1B |
| Interest CoverageEBIT ÷ Interest expense | -7.33x | 4.53x | 3.10x | 67.24x | 6.38x |
Total Returns (Dividends Reinvested)
HCI leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HCI five years ago would be worth $20,530 today (with dividends reinvested), compared to $4,866 for FTRE. Over the past 12 months, FTRE leads with a +176.6% total return vs HCI's +2.4%. The 3-year compound annual growth rate (CAGR) favors HCI at 45.7% vs FTRE's -21.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.4% | +2.5% | -20.7% | -16.7% | -10.1% |
| 1-Year ReturnPast 12 months | +176.6% | +7.2% | +16.5% | +2.4% | +32.8% |
| 3-Year ReturnCumulative with dividends | -51.3% | +32.0% | -5.9% | +209.6% | -4.2% |
| 5-Year ReturnCumulative with dividends | -51.3% | -3.2% | -23.8% | +105.3% | -46.9% |
| 10-Year ReturnCumulative with dividends | -51.3% | -18.8% | +166.5% | +436.8% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -21.3% | +9.7% | -2.0% | +45.7% | -1.4% |
Risk & Volatility
PRA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PRA is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than FTRE's 2.35 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRA currently trades 99.0% from its 52-week high vs IQV's 72.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.35x | 0.05x | 1.33x | 0.39x | 1.52x |
| 52-Week HighHighest price in past year | $18.67 | $24.85 | $247.05 | $210.50 | $228.88 |
| 52-Week LowLowest price in past year | $3.97 | $22.72 | $134.65 | $136.37 | $131.30 |
| % of 52W HighCurrent price vs 52-week peak | +83.4% | +99.0% | +72.3% | +72.6% | +79.5% |
| RSI (14)Momentum oscillator 0–100 | 82.8 | 48.4 | 58.5 | 48.7 | 57.2 |
| Avg Volume (50D)Average daily shares traded | 1.4M | 793K | 1.6M | 167K | 806K |
Analyst Outlook
Evenly matched — IQV and HCI each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: FTRE as "Hold", PRA as "Hold", IQV as "Buy", HCI as "Buy", CRL as "Buy". Consensus price targets imply 26.3% upside for IQV (target: $226) vs -25.5% for PRA (target: $18). HCI is the only dividend payer here at 0.98% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.83 | $18.33 | $225.63 | $126.50 | $205.43 |
| # AnalystsCovering analysts | 12 | 11 | 44 | 14 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +1.0% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 2 | 2 | 1 |
| Dividend / ShareAnnual DPS | — | — | — | $1.50 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.1% | +0.1% | +4.0% |
HCI leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). PRA leads in 1 (Risk & Volatility). 1 tied.
FTRE vs PRA vs IQV vs HCI vs CRL: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FTRE or PRA or IQV or HCI or CRL a better buy right now?
For growth investors, HCI Group, Inc.
(HCI) is the stronger pick with 20. 2% revenue growth year-over-year, versus -2. 7% for ProAssurance Corporation (PRA). HCI Group, Inc. (HCI) offers the better valuation at 6. 1x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FTRE or PRA or IQV or HCI or CRL?
On trailing P/E, HCI Group, Inc.
(HCI) is the cheapest at 6. 1x versus ProAssurance Corporation at 24. 9x. On forward P/E, HCI Group, Inc. is actually cheaper at 9. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: HCI Group, Inc. wins at 0. 19x versus IQVIA Holdings Inc. 's 0. 35x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — FTRE or PRA or IQV or HCI or CRL?
Over the past 5 years, HCI Group, Inc.
(HCI) delivered a total return of +105. 3%, compared to -51. 3% for Fortrea Holdings Inc. (FTRE). Over 10 years, the gap is even starker: HCI returned +436. 8% versus FTRE's -51. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FTRE or PRA or IQV or HCI or CRL?
By beta (market sensitivity over 5 years), ProAssurance Corporation (PRA) is the lower-risk stock at 0.
05β versus Fortrea Holdings Inc. 's 2. 35β — meaning FTRE is approximately 4801% more volatile than PRA relative to the S&P 500. On balance sheet safety, HCI Group, Inc. (HCI) carries a lower debt/equity ratio of 6% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — FTRE or PRA or IQV or HCI or CRL?
By revenue growth (latest reported year), HCI Group, Inc.
(HCI) is pulling ahead at 20. 2% versus -2. 7% for ProAssurance Corporation (PRA). On earnings-per-share growth, the picture is similar: HCI Group, Inc. grew EPS 179. 8% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, HCI leads at 22. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FTRE or PRA or IQV or HCI or CRL?
HCI Group, Inc.
(HCI) is the more profitable company, earning 33. 2% net margin versus -36. 2% for Fortrea Holdings Inc. — meaning it keeps 33. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCI leads at 47. 7% versus -1. 1% for FTRE. At the gross margin level — before operating expenses — HCI leads at 73. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FTRE or PRA or IQV or HCI or CRL more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, HCI Group, Inc. (HCI) is the more undervalued stock at a PEG of 0. 19x versus IQVIA Holdings Inc. 's 0. 35x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, HCI Group, Inc. (HCI) trades at 9. 2x forward P/E versus 23. 0x for Fortrea Holdings Inc. — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IQV: 26. 3% to $225. 63.
08Which pays a better dividend — FTRE or PRA or IQV or HCI or CRL?
In this comparison, HCI (1.
0% yield) pays a dividend. FTRE, PRA, IQV, CRL do not pay a meaningful dividend and should not be held primarily for income.
09Is FTRE or PRA or IQV or HCI or CRL better for a retirement portfolio?
For long-horizon retirement investors, HCI Group, Inc.
(HCI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 39), 1. 0% yield, +436. 8% 10Y return). Fortrea Holdings Inc. (FTRE) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HCI: +436. 8%, FTRE: -51. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FTRE and PRA and IQV and HCI and CRL?
These companies operate in different sectors (FTRE (Healthcare) and PRA (Financial Services) and IQV (Healthcare) and HCI (Financial Services) and CRL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FTRE is a small-cap quality compounder stock; PRA is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock; HCI is a small-cap high-growth stock; CRL is a small-cap quality compounder stock. HCI pays a dividend while FTRE, PRA, IQV, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.